{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:25:56Z","timestamp":1780374356984,"version":"3.54.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The area of myocardial infarction continues to expand for hours after reperfusion. The injured but viable myocardium may be salvaged if the signals leading to cell death are interrupted. Activation of the caspase-1 inflammasome in the heart shortly after ischemia\u2013reperfusion contributes to the final infarct size. Plasma-derived \u03b1-1 anti-trypsin (AAT) has shown to inhibit inflammasome formation in vitro and in vivo. To explore the potential translational clinical value of AAT as a therapeutic, we conducted a series of preclinical experiments designed to simulate clinically relevant scenarios.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Adult male CD1 mice were used. The left anterior descending coronary artery was ligated for 30 or 75 minutes followed by reperfusion, to explore different severity of ischemic injury. Plasma-derived AAT (Prolastin C) was administered intraperitoneally after reperfusion, without pretreatment, exploring 3 different doses (60, 120, and 180 mg\/kg). In a subgroup of mice, we administered Prolastin C with a delay of 30 minutes after reperfusion to simulate the clinical context of delayed administration, and we also used a model of permanent coronary artery ligation without reperfusion. Finally, we tested whether a single dose at reperfusion was sufficient to maintain a benefit in the longer term (7 days). Infarct size was measured by 3 different and independent methodologies: pathology, plasma levels of troponin I, and wall motion abnormalities at echocardiography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Prolastin C given at reperfusion after 30 minutes of ischemia provided a powerful reduction in infarct size (&gt;50% reduction in all methodology used, all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01) without a clear dose-dependent response. Prolongation of ischemia to 75 minutes nor a delay in treatment by 30 minutes after reperfusion had any negative impact on Prolastin C effects. A single dose given at reperfusion was as effective as multiple daily doses. When given to the mouse without reperfusion, Prolastin C failed to reduce infarct size.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Plasma-derived AAT (Prolastin C) given as an adjunct to reperfusion powerfully limits the final infarct size across a wide range of experiments in the mouse reproducing clinically relevant scenarios, such as variable duration of ischemia, delay in administration in the drug, and a large therapeutic index.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fjc.0000000000000474","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T12:05:00Z","timestamp":1487073900000},"page":"273-278","source":"Crossref","is-referenced-by-count":20,"title":["A Preclinical Translational Study of the Cardioprotective Effects of Plasma-Derived Alpha-1 Anti-trypsin in Acute Myocardial Infarction"],"prefix":"10.1097","volume":"69","author":[{"given":"Adolfo G.","family":"Mauro","sequence":"first","affiliation":[{"name":"VCU Pauley Heart Center;"},{"name":"VCU Johnson Research Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mezzaroma","sequence":"additional","affiliation":[{"name":"VCU Johnson Research Center;"},{"name":"Department of Pharmacotherapy and Outcome Sciences, School of Pharmacy; and"},{"name":"Department of Surgery, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"},{"name":"VCU Johnson Research Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyush","family":"Narayan","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"},{"name":"VCU Johnson Research Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco G.","family":"Del Buono","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialessia","family":"Capuano","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Prestamburgo","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Catapano","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi N.","family":"Salloum","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"},{"name":"VCU Johnson Research Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Toldo","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center;"},{"name":"VCU Johnson Research Center;"},{"name":"Department of Surgery, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.CIR.56.5.786","article-title":"The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs","volume":"56","author":"Reimer","year":"1977","journal-title":"Circulation"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2015.02.032","article-title":"Evolving therapies for myocardial ischemia\/reperfusion injury","volume":"65","author":"Ib\u00e1\u00f1ez","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2016.02.043","article-title":"Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse","volume":"209","author":"Toldo","year":"2016","journal-title":"Int J Cardiol."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.110.982777","article-title":"Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia\/reperfusion injury","volume":"123","author":"Kawaguchi","year":"2011","journal-title":"Circulation"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"J Cardiovasc Pharmacol."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"J Cardiovasc Pharmacol."},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvt091","article-title":"The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury","volume":"99","author":"Sandanger","year":"2013","journal-title":"Cardiovasc Res."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"ehw247","DOI":"10.1093\/eurheartj\/ehw247","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","author":"van Hout","year":"2016","journal-title":"Eur Heart J."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1189\/jlb.0208145","article-title":"Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood","volume":"85","author":"Pott","year":"2009","journal-title":"J Leukoc Biol."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.yjmcc.2011.05.003","article-title":"Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia\u2013reperfusion injury","volume":"51","author":"Toldo","year":"2011","journal-title":"J Mol Cell Cardiol."},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/FJC.0000000000000383","article-title":"Recombinant human alpha-1 antitrypsin-Fc fusion protein reduces mouse myocardial inflammatory injury after ischemia\u2013reperfusion independent of elastase inhibition","volume":"68","author":"Toldo","year":"2016","journal-title":"J Cardiovasc Pharmacol."},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2007.04.067","article-title":"All is not well in the world of translational research","volume":"50","author":"Unger","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jacbts.2016.06.012","article-title":"Mitochondrial membrane permeability inhibitors in acute myocardial infarction","volume":"1","author":"Trankle","year":"2016","journal-title":"JACC Basic Transl Sci."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"e002360","DOI":"10.1161\/JAHA.112.002360","article-title":"Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse","volume":"1","author":"Toldo","year":"2012","journal-title":"J Am Heart Assoc."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/15412555.2013.800852","article-title":"Safety and pharmacokinetics of 120 mg\/kg versus 60 mg\/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)","volume":"10","author":"Campos","year":"2013","journal-title":"COPD"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/FJC.0b013e3181f9a905","article-title":"Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3K\u03b3) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice","volume":"56","author":"Seropian","year":"2010","journal-title":"J Cardiovasc Pharmacol."},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1089\/ars.2014.5989","article-title":"The inflammasome in myocardial injury and cardiac remodeling","volume":"22","author":"Toldo","year":"2015","journal-title":"Antioxid Redox Signal."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2014.09.043","article-title":"Effects of Prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am J Cardiol."},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","article-title":"Long-term trends in the incidence of heart failure after myocardial infarction","volume":"118","author":"Velagaleti","year":"2008","journal-title":"Circulation"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005344-201705000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:17:42Z","timestamp":1694395062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201705000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000474","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}